NEW YORK (GenomeWeb News) – SQI Diagnostics and Algorithme Pharma today said they are co-developing a proof-of-concept assay for immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

The assay is based on SQI's Ig Plex multiplexing technology and is expected to be available on all of the Toronto-based firm's fully automated analytical systems, including its SQIDlite and SQIDworks platforms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.